Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Brian Moore who wrote (17664)	3/19/1998 11:29:00 AM
From: Andreas Helke	Respond to of 32384

Finding the optimal time to invest into a biotech is extremely difficult. I don't yet have figured that out. I considered Ligand an excellent long term investment candidate when it was below $12 from december to february. After all we had the same $20 to $30 medium term price targets that we still have now. And the only difference is that now Ligand is more likely to actually reach those targets. And that we know that Ligand has actually started its expected earnings growth by reducing its losses. This earnings surprise was the trigger for the current rally. At current prices I consider Ligand just one of several promising biotechs. But I don't see a really good reason to sell any shares. If I waited until Ligand reaches $20 - $30 I could only afford half as much shares which would seriously reduce the long term potential of this investment. And I would have the risk that maybe the only difference would be that I paid full price for the company instead of acquiring it at a discount. Andreas